This was the stock's second consecutive day of gains.

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $441.00. The company’s shares closed yesterday ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

If you’re on the fence about investing in Vertex Pharmaceuticals Incorporated, Gilead Sciences or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... (from the recent acquisition of Alpine Immune Sciences), and alpha-1 antitrypsin disease.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Vertex Pharmaceuticals Inc. notched two FDA victories on Friday for its cystic fibrosis medicines, increasing the number of patients eligible for its drugs and likely boosting its own future revenue.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to ...